These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27292781)

  • 1. Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis.
    Dang YP; Chen YF; Li YQ; Zhao L
    Mini Rev Med Chem; 2017; 17(4):338-350. PubMed ID: 27292781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep vein thrombosis and novel oral anticoagulants: a clinical review.
    Burgazli KM; Atmaca N; Mericliler M; Parahuleva M; Erdogan A; Daebritz SH
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3123-31. PubMed ID: 24338453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reviparin sodium - a new low molecular weight heparin.
    Breddin HK
    Expert Opin Pharmacother; 2002 Feb; 3(2):173-82. PubMed ID: 11829731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
    Mangiafico RA; Mangiafico M
    Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.
    Mekaj YH; Mekaj AY; Duci SB; Miftari EI
    Ther Clin Risk Manag; 2015; 11():967-77. PubMed ID: 26150723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Inhibitors of FXa.
    Guo L; Ma S
    Curr Drug Targets; 2015; 16(11):1207-32. PubMed ID: 25981610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis?
    Brodmann M
    Hamostaseologie; 2013 Aug; 33(3):218-24. PubMed ID: 23681109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.
    Hull RD; Gersh MH
    Curr Med Res Opin; 2015 Feb; 31(2):197-210. PubMed ID: 25299352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant therapy: basic principles, classic approaches and recent developments.
    Sinauridze EI; Panteleev MA; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):482-93. PubMed ID: 22732252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer anticoagulants in cardiovascular disease: a systematic review of the literature.
    Maan A; Padmanabhan R; Shaikh AY; Mansour M; Ruskin JN; Heist EK
    Cardiol Rev; 2012; 20(5):209-21. PubMed ID: 22370770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
    Nutescu EA; Helgason CM
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):82S-87S. PubMed ID: 15317403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
    Chan NC; Bhagirath V; Eikelboom JW
    Vasc Health Risk Manag; 2015; 11():343-51. PubMed ID: 26170684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in anticoagulants: Past, present and future.
    Weitz JI; Harenberg J
    Thromb Haemost; 2017 Jun; 117(7):1283-1288. PubMed ID: 28594426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.